Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole. The relation between fluconazole therapy and IC remains controversial. In a retrospective review covering 5 years, we identified 203 cases of IC, 71 (35%) of which were due to non-albicans species. Eight cases were caused by C. krusei: four of the patients involved had leukemia, two had breast cancer, one had end-stage liver disease, and one had undergone abdominal trauma. None of these patients received fluconazole. Surveillance cultures detected colonization with C. krusei before the onset of symptoms in seven cases. The median time from colonization to IC diagnosis was 10 days. Of six patients with neutropenia, five were neutropenic at IC diagnosis. Concomitant infections were Common; four patients had both bacteremia and invasive aspergillosis. C. krusei was considered the immediate cause of five of the seven deaths among this group of patients. These eight cases extend the range of immunocompromised conditions in which IC caused by C. krusei develops in the absence of fluconazole therapy.

Original languageEnglish (US)
Pages (from-to)342-347
Number of pages6
JournalClinical Infectious Diseases
Volume20
Issue number2
DOIs
StatePublished - Feb 1995

Fingerprint

Invasive Candidiasis
Fluconazole
Immunocompromised Host
Candida
Infection
Leukemia
End Stage Liver Disease
Aspergillosis
Bacteremia
Neutropenia
Bone Marrow Transplantation
Therapeutics
Breast Neoplasms
Wounds and Injuries

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{6a577864bffd4c6aacb490f56b3ab97f,
title = "Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole",
abstract = "Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole. The relation between fluconazole therapy and IC remains controversial. In a retrospective review covering 5 years, we identified 203 cases of IC, 71 (35{\%}) of which were due to non-albicans species. Eight cases were caused by C. krusei: four of the patients involved had leukemia, two had breast cancer, one had end-stage liver disease, and one had undergone abdominal trauma. None of these patients received fluconazole. Surveillance cultures detected colonization with C. krusei before the onset of symptoms in seven cases. The median time from colonization to IC diagnosis was 10 days. Of six patients with neutropenia, five were neutropenic at IC diagnosis. Concomitant infections were Common; four patients had both bacteremia and invasive aspergillosis. C. krusei was considered the immediate cause of five of the seven deaths among this group of patients. These eight cases extend the range of immunocompromised conditions in which IC caused by C. krusei develops in the absence of fluconazole therapy.",
author = "Iwen, {Peter C.} and Kelly, {Dianne M.} and Reed, {Elizabeth C.} and Hinrichs, {Steven H.}",
year = "1995",
month = "2",
doi = "10.1093/clinids/20.2.342",
language = "English (US)",
volume = "20",
pages = "342--347",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole

AU - Iwen, Peter C.

AU - Kelly, Dianne M.

AU - Reed, Elizabeth C.

AU - Hinrichs, Steven H.

PY - 1995/2

Y1 - 1995/2

N2 - Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole. The relation between fluconazole therapy and IC remains controversial. In a retrospective review covering 5 years, we identified 203 cases of IC, 71 (35%) of which were due to non-albicans species. Eight cases were caused by C. krusei: four of the patients involved had leukemia, two had breast cancer, one had end-stage liver disease, and one had undergone abdominal trauma. None of these patients received fluconazole. Surveillance cultures detected colonization with C. krusei before the onset of symptoms in seven cases. The median time from colonization to IC diagnosis was 10 days. Of six patients with neutropenia, five were neutropenic at IC diagnosis. Concomitant infections were Common; four patients had both bacteremia and invasive aspergillosis. C. krusei was considered the immediate cause of five of the seven deaths among this group of patients. These eight cases extend the range of immunocompromised conditions in which IC caused by C. krusei develops in the absence of fluconazole therapy.

AB - Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole. The relation between fluconazole therapy and IC remains controversial. In a retrospective review covering 5 years, we identified 203 cases of IC, 71 (35%) of which were due to non-albicans species. Eight cases were caused by C. krusei: four of the patients involved had leukemia, two had breast cancer, one had end-stage liver disease, and one had undergone abdominal trauma. None of these patients received fluconazole. Surveillance cultures detected colonization with C. krusei before the onset of symptoms in seven cases. The median time from colonization to IC diagnosis was 10 days. Of six patients with neutropenia, five were neutropenic at IC diagnosis. Concomitant infections were Common; four patients had both bacteremia and invasive aspergillosis. C. krusei was considered the immediate cause of five of the seven deaths among this group of patients. These eight cases extend the range of immunocompromised conditions in which IC caused by C. krusei develops in the absence of fluconazole therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028887667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028887667&partnerID=8YFLogxK

U2 - 10.1093/clinids/20.2.342

DO - 10.1093/clinids/20.2.342

M3 - Article

C2 - 7742440

AN - SCOPUS:0028887667

VL - 20

SP - 342

EP - 347

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -